Concord Biotech Key Ratios
NSE: CONCORDBIO | BSE: 543960
₹554.80
As on 17-Nov-2026IST
Market cap
₹11,617 Cr
Revenue (TTM)
₹1,170 Cr
P/E Ratio
41.1
P/B Ratio
5.6
Div. Yield
0.7 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 20.03 | 25.10 | 4.02 | 6.44 | 11.32 |
| EBIT | 33.80 | 22.69 | -11.95 | -4.46 | -0.47 |
| Net Profit | 20.72 | 11.13 | -12.06 | -2.18 | 1.99 |
| EPS | 20.72 | 11.12 | -12.81 | -2.46 | 2.13 |
| Book Value | -- | -- | 11.27 | 16.07 | 15.08 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 34.54 | 33.74 | 28.15 | 27.82 | 37.70 |
| Net Margin
| 27.58 | 26.68 | 22.94 | 23.41 | 29.86 |
| Return on equity
| 19.24 | 18.88 | 13.92 | 13.54 | 22.26 |
| Return on Capital
| 25.66 | 25.03 | -- | 18.04 | 29.62 |
| Return on Assets
| 17.09 | 15.91 | 12.86 | 12.15 | 19.90 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
18.04
|
29.62
|
29.13
|
26.70
|
|
Peer Median
|
--
|
12.41
|
16.46
|
15.49
|
--
|
ROE
13.92
Higher than Peers by 4.84
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
13.92
|
13.54
|
22.26
|
21.88
|
20.06
|
|
Peer Median
|
9.08
|
13.36
|
13.87
|
14.72
|
--
|
ROA
12.86
Higher than Peers by 5.59
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
12.86
|
12.15
|
19.90
|
19.17
|
15.92
|
|
Peer Median
|
7.27
|
7.23
|
8.04
|
7.19
|
--
|
EBIT Margin
28.15
Higher than Peers by 18.91
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
28.15
|
27.82
|
37.70
|
37.23
|
34.52
|
|
Peer Median
|
9.25
|
17.33
|
10.05
|
10.28
|
--
|
Net Margin
22.94
Higher than Peers by 14.49
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
22.94
|
23.41
|
29.86
|
29.32
|
27.02
|
|
Peer Median
|
8.46
|
11.16
|
9.11
|
6.78
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
31.63
|
35.50
|
35.57
|
34.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
4.02
Lower than Peers by 2.62
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
4.02
|
-12.10
|
18.01
|
19.20
|
19.67
|
|
Peer Median
|
6.64
|
26.57
|
7.17
|
10.56
|
--
|
EBIT Growth
-11.95
Lower than Peers by 11.64
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-11.95
|
-35.14
|
19.51
|
28.54
|
31.57
|
|
Peer Median
|
-0.31
|
31.63
|
12.05
|
6.17
|
--
|
Net Profit Growth
-12.06
Lower than Peers by 19.64
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-12.06
|
-30.25
|
20.62
|
28.33
|
37.25
|
|
Peer Median
|
7.58
|
26.27
|
22.15
|
27.97
|
--
|
EPS Growth
-12.81
Lower than Peers by 13.89
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
-12.81
|
-29.80
|
20.62
|
28.33
|
37.25
|
|
Peer Median
|
1.08
|
24.54
|
8.80
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
11.27
|
18.74
|
18.34
|
16.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
--
|
0.00
|
0.00
|
0.02
|
|
Peer Median
|
0.02
|
0.17
|
0.03
|
0.05
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
--
|
0.00
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.40
Higher than Peers by 4.00
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
6.40
|
7.39
|
6.17
|
6.30
|
3.79
|
|
Peer Median
|
2.40
|
2.09
|
2.20
|
1.93
|
--
|
Quick Ratio
4.43
Higher than Peers by 2.72
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
4.43
|
5.46
|
4.87
|
4.84
|
2.69
|
|
Peer Median
|
1.71
|
1.62
|
1.72
|
1.59
|
--
|
Interest Coverage
1,593.82
Higher than Peers by 1,584.02
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
1,593.82
|
419.57
|
475.76
|
130.57
|
33.85
|
|
Peer Median
|
9.79
|
10.26
|
12.28
|
12.45
|
--
|
Operating Efficiency
Debtors to sales
35.24
Higher than Peers by 8.21
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
35.24
|
43.63
|
43.47
|
34.38
|
32.09
|
|
Peer Median
|
27.04
|
32.97
|
26.23
|
23.97
|
--
|
Asset Turnover
0.54
Lower than Peers by 0.15
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
0.54
|
0.49
|
0.64
|
0.63
|
0.57
|
|
Peer Median
|
0.69
|
0.65
|
0.74
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
169.86
|
132.49
|
111.87
|
108.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
97.92
|
68.07
|
75.42
|
87.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
159.68
|
123.94
|
149.88
|
179.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
--
|
108.11
|
76.63
|
37.41
|
16.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
41.13
Higher than Peers by 0.55
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
41.13
|
40.73
|
47.19
|
51.68
|
--
|
|
Peer Median
|
40.58
|
41.13
|
39.17
|
40.74
|
--
|
Price / Book Value
5.57
Higher than Peers by 1.98
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
5.57
|
5.27
|
9.67
|
10.43
|
--
|
|
Peer Median
|
3.59
|
4.52
|
3.61
|
3.87
|
--
|
Dividend Yield
0.68
Higher than Peers by 0.58
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
0.68
|
0.74
|
0.64
|
0.57
|
--
|
|
Peer Median
|
0.10
|
0.10
|
0.19
|
0.20
|
--
|
EV/EBITDA
25.65
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
25.65
|
25.25
|
31.81
|
34.08
|
0.00
|
|
Peer Median
|
--
|
39.49
|
28.79
|
25.41
|
--
|
Market Cap
11,617
Higher than Peers by 6,372
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Concord Biotech
|
11,617
|
10,628
|
17,537
|
15,922
|
--
|
|
Peer Median
|
5,245
|
5,245
|
3,944
|
2,959
|
--
|